A Phase 4 interventional study of Dextro-Amphetamin and Glucose in Stroke, sponsored by Reha Rheinfelden. Terminated at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-12-13.
Sponsored by Reha Rheinfelden · Phase 4, Interventional, and Treatment
Among 215 studies in Stroke with a site in Switzerland — 46 open to participants now, 59 under way, 6 of them phase 3. Stroke · Switzerland.
Among the 215 studies in Stroke with a site in Switzerland, this one is the 127th largest by enrollment of the 147 interventional ones that give a count, is one of 2 that started in 2001, is one of 7 in phase 4, and was the 18th registered.
8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.
Browse Stroke studies →46 of the 215 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Switzerland, Belgium, Germany and 3 more countries
Ages 18+
Ecole Polytechnique Fédérale de Lausanne · Sites in Switzerland
Ages 18–70
Centre Hospitalier Universitaire Vaudois · Sites in Switzerland
Ages 18–85
School of Health Sciences Geneva · Sites in Switzerland
Ages 18+
Sigmund Freud PrivatUniversitat · Sites in Switzerland, Austria, Germany
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 1,415 Stroke studies recruiting now, 697 (49%) set no upper age limit and 280 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
215 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 37 · Phase 4 7
First in 1998; this study’s year is marked. 2 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 49 across 6,024 interventional studies indexed under Stroke.
Median enrollment 79 across the 147 interventional studies, 200 across the 68 observational. Of the 134 that completed or were terminated, 19 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 215 have an industry lead sponsor. The 10 most frequent:
Reha Rheinfelden is the lead sponsor of 5 studies on the registry; none are open to participants now.
Reha Rheinfelden has 4 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
11 of the studies in Stroke with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02756091Insel Gruppe AG, University Hospital BernInternational Intracranial Dissection Study | 2026-11-30 |
| NCT06466772University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT07739134ETH ZurichMultimodal Tracking of Therapy Activity and Effort During Rehabilitation | 2026-12-30 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT07444151School of Health Sciences GenevaPost-Stroke Fatigue Perception Study (ReFast) | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 215 studies in Stroke with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to evaluate the effect of Dextro-amphetamin added to physiotherapy on motor recovery in patients after stroke. The study is a double-blinded placebo-controlled randomised controlled trial.
Patients after a first-ever ischemic stroke will receive Dexamphetamine (10mg) twice per week for a duration of five weeks after a baseline phase of two weeks.
The outcome measure focuses on motor recovery and will be assessed:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dextro-Amphetamin
Other: Glucose
After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour. The treatment of the control group will be the same as for the experimental group except the content of the drug capsule.
Chedoke-McMaster Stroke Assessment (motor impairment measure)
Time frame: Over the whole duration of the study (2001 to 2006, ten times for each patient)
The record gives a start of Jan 2001 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Reha Rheinfelden